AlgiPharma together with FMC Biopolymer and SINTEF are part of the award winning research consortium co-ordinated by Dr. Gudmund Skjaak-Braek at the Norwegian National Biotechnology Institute (NTNU). AlgiPharma will receive four million Norwegian kroner (approx. 700.000 USD) over a 4 year period to fund its continuing research program in the development of its ground breaking alginate pharmaceutical. The consortium funding also allows NTNU and SINTEF to continue their critical basic research into alginate technologies, capitalizing on decades of experience and expertise at these institutions.
For further information, please contact:
Philip D. Rye R&D Director; email@example.com